NKG2D

NKG2D 분자 정보

영어 이름NKG2-D type II integral membrane protein시판 약물 수0
임상 약물 수9표적 별명Killer cell lectin-like receptor subfamily K member 1,NK cell receptor D,NKG2-D-activating NK receptor,CD314,D12S2489E,KLR,DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence,Killer Cell Lectin Like Receptor K1,NKG2-D,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,KLRK1,CD314 Antigen
최고 연구 개발 단계Phase 2 Clinical
영어 이름NKG2-D type II integral membrane protein
표적 별명Killer cell lectin-like receptor subfamily K member 1,NK cell receptor D,NKG2-D-activating NK receptor,CD314,D12S2489E,KLR,DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence,Killer Cell Lectin Like Receptor K1,NKG2-D,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,KLRK1,CD314 Antigen
시판 약물 수0
임상 약물 수9
최고 연구 개발 단계Phase 2 Clinical

NKG2D 제품 목록

  • 속성

    Protein (7)

  • 제품 라이브러리

    온라인 (7)

  • Human (6)Cynomolgus (1)

  • 태그

    Fc Tag (2)His Tag (2)Mouse IgG Fc Tag (1)Avi Tag & Fc Tag (1)His Tag & Avi Tag (1)

  • 마커

    Unconjugated (4)FITC Labeled (1)Biotin-labeled (2)

NKG2D분자 배경

NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.

NKG2D분자 별명

NKG2D,CD314,KLRK1,NK cell receptor D

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
TesnatilimabIPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555Phase 2 ClinicalInnate PharmaAlopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Crohn Disease; Inflammation
상세
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology)Phase 2 ClinicalChongqing Sidemu Biotechnology Technology Co LtdCoronavirus Disease 2019 (COVID-19); Hematologic Neoplasms
상세
NKG2D CAR-T CellPhase 1 ClinicalHangzhou Cheetah Cell Therapeutics Co LtdColorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Ovarian Neoplasms
상세
anti-NKG2D CAR NK-cell therapy (Xinxiang Medical University)Phase 1 ClinicalXinxiang Medical UniversitySolid tumours
상세
Anti-NKG2D CAR-NK cells therapy (CNK Cell Therapeutics)Phase 1 ClinicalCNK Cell Therapeutics Co LtdSolid tumours
상세
Anti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics)Phase 1 ClinicalHangzhou CNK Therapeutics Co LtdPancreatic Neoplasms; Solid tumours
상세
NKG2D CAR-T Cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdColorectal Neoplasms; Leukemia, Myeloid, Acute
상세
Anti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)ClinicalLeukemia, Myeloid, Acute; Ovarian Neoplasms
상세
NKG2D CAR-T cell therapy (Uwell Biopharma)UWN2DClinicalUwell BiopharmaNeoplasms
상세
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호